Pre-exposure prophylaxis awareness, interest, and modality preferences to prevent HIV among cisgender women in the Dominican Republic and the United States
7 affiliations
- 1School of Public Health, Rutgers, The State University of New Jersey, Piscataway, Washington, DC, United States
- 2Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States
- 3Kephi Public Health, New York, NY, United States
- 4MedStar Health, Washington, DC, United States
- 5ViiV Healthcare, Durham, NC, United States
- 6Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, United States
- 7Instituto Dermatológico y Cirugía de Piel, Santo Domingo, Dominican Republic
Abstract
Introduction: Significant inequities in HIV incidence and prevalence exist among cisgender women (hereafter women), including a disproportionate burden of the epidemic among Black women in the United States and female sex workers globally. Women have limited awareness of and access to pre–exposure prophylaxis (PrEP) for HIV pharmacoprevention.
Methods: We explored PrEP awareness, interest, and modality preferences [daily oral vs. long–acting injectable (LAI) PrEP] in Santo Domingo, Dominican Republic (DR) and Washington, DC (DC) in the United States through in–depth interviews (IDIs) with women (N = 40) and healthcare providers (HCPs; N = 20) in 2021–2022 and surveys of women (N = 602) in 2022–2023. Thematic analysis andmultivariate regression were utilized.
Results: Across settings, women were aged ≥18 years and HIV–negative; most were Black or multiracial, single, in their 30s, with >1 child. In IDIs, women characterized PrEP as an empowerment tool and welcomed modality options; HCPs across sites relayed a lack of comfort and preparation to address the unique needs of women and discuss LAI PrEP. In surveys, women reported low PrEP awareness and use: 29% (DC) and 6% (DR) had heard of daily oral PrEP, <6% had heard of LAI PrEP across sites, and 3% (DC) and 1% (DR) had ever used PrEP. Strong interest in taking PrEP varied (DC, 5%; DR, 80%). Modality preferences were similar, with most preferring LAI vs. daily oral PrEP (DC, 73%; DR, 71%). Across sites, preference for LAI PrEP was inversely associated with concern for injection pain/tenderness. In DC, LAI preference was associated with a higher score on a PrEP optimization/ considerations scale. In the DR, LAI preference was associated with injectable medication/contraception experience and alcohol use and inversely associated with PrEP stigma and partner violence.
Discussion: Diverse groups of women have shared and unique drivers of PrEP modality preferences which should be considered when developing and tailoring multi–level interventions to promote PrEP awareness and uptake among women. These interventions should address social determinants and side effects and include HCP training and tools that promote shared decision–making.
Related
- ASSESSING THE ACCEPTABILITY OF, AND WILLINGNESS TO PAY FOR, EVENT-DRIVEN PRE-EXPOSURE PROPHYLAXIS AMONG CISGENDER MEN IN CAPE TOWN, SOUTH AFRICA
- Awareness and Prescribing Practices for Doxycycline Post‐Exposure Prophylaxis (doxyPEP) Among Healthcare Providers Delivering Sexual Health Care in Australia: A Cross‐Sectional Survey
- A scoping review of pre-exposure prophylaxis awareness, acceptability, uptake, adherence, and HIV-related risk behaviors among university students in South Africa
- Awareness of and Hypothetical Willingness to Use Long-Acting Injectable Cabotegravir and Associated Factors Among Oral Pre-Exposure Prophylaxis Users Who Obtained the Medicine Online in China: Web-Based Cross-Sectional Study.
- Immune correlates of protection are exposure-dependent: evidence from the Dominican Republic
BibTeX
@article{kerrigan2026preexposure,
title = {{Pre-exposure prophylaxis awareness, interest, and modality preferences to prevent HIV among cisgender women in the Dominican Republic and the United States}},
author = {Deanna Kerrigan and Wendy Davis and Allison O’Rourke and Noya Galai and Andrea Mantsios and Rachel K. Scott and Patricia Moriarty and Aimee A. Metzner and Alan Oglesby and Tahilin Sanchez Karver and Tamara Taggart and Clare Barrington and Breana J. Uhrig Castonguay and Kimi Yonamine and Hoisex Gomez and Martha Perez and Yeycy Donastorg},
journal = {Frontiers in Global Women's Health},
year = {2026},
month = oct,
doi = {10.3389/fgwh.2026.1817411},
url = {https://doi.org/10.3389/fgwh.2026.1817411},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Pre-exposure prophylaxis awareness, interest, and modality preferences to prevent HIV among cisgender women in the Dominican Republic and the United States
AU - Deanna Kerrigan
AU - Wendy Davis
AU - Allison O’Rourke
AU - Noya Galai
AU - Andrea Mantsios
AU - Rachel K. Scott
AU - Patricia Moriarty
AU - Aimee A. Metzner
AU - Alan Oglesby
AU - Tahilin Sanchez Karver
AU - Tamara Taggart
AU - Clare Barrington
AU - Breana J. Uhrig Castonguay
AU - Kimi Yonamine
AU - Hoisex Gomez
AU - Martha Perez
AU - Yeycy Donastorg
PY - 2026
DA - 2026/10/21
JO - Frontiers in Global Women's Health
DO - 10.3389/fgwh.2026.1817411
UR - https://doi.org/10.3389/fgwh.2026.1817411
AB - Introduction: Significant inequities in HIV incidence and prevalence exist among cisgender women (hereafter women), including a disproportionate burden of the epidemic among Black women in the United States and female sex workers globally. Women have limited awareness of and access to pre–exposure prophylaxis (PrEP) for HIV pharmacoprevention. Methods: We explored PrEP awareness, interest, and modality preferences [daily oral vs. long–acting injectable (LAI) PrEP] in Santo Domingo, Dominican Republic (DR) and Washington, DC (DC) in the United States through in–depth interviews (IDIs) with women (N = 40) and healthcare providers (HCPs; N = 20) in 2021–2022 and surveys of women (N = 602) in 2022–2023. Thematic analysis andmultivariate regression were utilized. Results: Across settings, women were aged ≥18 years and HIV–negative; most were Black or multiracial, single, in their 30s, with >1 child. In IDIs, women characterized PrEP as an empowerment tool and welcomed modality options; HCPs across sites relayed a lack of comfort and preparation to address the unique needs of women and discuss LAI PrEP. In surveys, women reported low PrEP awareness and use: 29% (DC) and 6% (DR) had heard of daily oral PrEP, <6% had heard of LAI PrEP across sites, and 3% (DC) and 1% (DR) had ever used PrEP. Strong interest in taking PrEP varied (DC, 5%; DR, 80%). Modality preferences were similar, with most preferring LAI vs. daily oral PrEP (DC, 73%; DR, 71%). Across sites, preference for LAI PrEP was inversely associated with concern for injection pain/tenderness. In DC, LAI preference was associated with a higher score on a PrEP optimization/ considerations scale. In the DR, LAI preference was associated with injectable medication/contraception experience and alcohol use and inversely associated with PrEP stigma and partner violence. Discussion: Diverse groups of women have shared and unique drivers of PrEP modality preferences which should be considered when developing and tailoring multi–level interventions to promote PrEP awareness and uptake among women. These interventions should address social determinants and side effects and include HCP training and tools that promote shared decision–making.
SN - 2673-5059
ER -